Interpretation of guideline for the prevention and treatment of hepatitis C (2022 version): Antiviral therapy for special populations
10.3969/j.issn.1001-5256.2023.07.008
- VernacularTitle:《丙型肝炎防治指南(2022年版)》解读：特殊人群抗病毒治疗
- Author:
Qinglei ZENG
1
;
Fanpu JI
2
Author Information
1. Department of Infectious Diseases, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China
2. Department of Infectious Diseases, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, China
- Publication Type:Guideline Interpretation
- Keywords:
Hepatitis C;
Therapeutics;
Practice Guideline
- From:
Journal of Clinical Hepatology
2023;39(7):1560-1563
- CountryChina
- Language:Chinese
-
Abstract:
In 2022, Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association, organized domestic experts to update the guideline for the prevention and treatment of hepatitis C from the aspects of epidemiology, population screening and prevention, laboratory testing, simplification of diagnostic processes and treatment regimens, and antiviral therapy for special populations. This article aims to interpret the treatment of special populations not specifically mentioned in the new guideline, including pregnant women and patients with hepatocellular carcinoma, as well as other issues that need to be solved, in order to provide a reference for clinicians in practical work.
